Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Workplace health promotion: how to help employees to stop smoking.

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Workplace health promotion: how to help employees to stop smoking. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 43 p. (Public health intervention guidance; no. 5). [22 references]

GUIDELINE STATUS

This is the current release of the guideline.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

  • July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

BRIEF SUMMARY CONTENT

 ** REGULATORY ALERT **
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

This document constitutes the Institute's formal guidance on how to encourage and support employees to stop smoking.

The recommendations in this section are presented without any reference to evidence statements. Appendix A in the original guideline document repeats the recommendations and lists their linked evidence statements.

Recommendation 1

Who should take action?

Employers

What action should they take?

  • Publicise the interventions identified in this guidance and make information on local stop smoking support services widely available at work. This information should include details on the type of help available, when and where, and how to access the services.
  • Be responsive to individual needs and preferences. Where feasible, and where there is sufficient demand, provide on-site stop smoking support.
  • Allow staff to attend smoking cessation services during working hours without loss of pay.
  • Develop a smoking cessation policy in collaboration with staff and their representatives as one element of an overall smoke-free workplace policy.

Recommendation 2

Who should take action?

Employees who want to stop smoking

What action should they take?

Contact local smoking cessation services, such as the NHS Stop Smoking Services, for information, advice and support.

Recommendation 3

Who should take action?

Employees and their representatives

What action should they take?

Encourage employers to provide advice, guidance and support to help employees who want to stop smoking.

Recommendation 4

Who should take action?

All those offering smoking cessation services including the NHS, independent or commercial organisations and employers

What action should they take?

Recommendation 5

Who should take action?

Managers of NHS Stop Smoking Services

What action should they take?

  • Offer support to employers who want to help their employees to stop smoking. Where appropriate and feasible, provide support on the employer's premises.
  • If initial demand exceeds the resources available, focus on the following:
    • Small and medium-sized enterprises (SMEs)
    • Enterprises where a high proportion of employees are on low pay
    • Enterprises where a high proportion of employees are from a disadvantaged background
    • Enterprises where a high proportion of employees are heavy smokers

Recommendation 6

Who should take action?

Strategic health authorities and primary care trusts.

What action should they take?

Ensure local NHS Stop Smoking Services are able to respond to fluctuations in demand, particularly before and after implementation of smoke-free legislation.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type and quality of supporting evidence is identified and graded for each recommendation (see Appendix A in the original guideline document).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Workplace health promotion: how to help employees to stop smoking. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 43 p. (Public health intervention guidance; no. 5). [22 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2007 Apr

GUIDELINE DEVELOPER(S)

National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

National Institute for Health and Clinical Excellence (NICE)

GUIDELINE COMMITTEE

NICE Project Team
Public Health Interventions Advisory Committee (PHIAC)

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

NICE Project Team Members: Professor Mike Kelly, CPHE Director; Tricia Younger, Associate Director; Dr Lesley Owen, Lead Analyst; Patti White, Analyst; Dr Hugo Crombie, Analyst; Dr Alastair Fischer, Health Economics Adviser

Public Health Interventions Advisory Committee (PHIAC) Members: Mrs Cheryll Adams, Professional Officer for Research and Practice Development with the Community Practitioners' and Health Visitors' Association (CPHVA); Professor Sue Atkinson, CBE Independent Consultant and Visiting Professor in the Department of Epidemiology and Public Health, University College London; Professor Michael Bury, Emeritus Professor of Sociology at the University of London and Honorary Professor of Sociology at the University of Kent; Professor Simon Capewell, Chair of Clinical Epidemiology, University of Liverpool; Professor K K Cheng, Professor of Epidemiology, University of Birmingham; Dr Richard Cookson, Senior Lecturer, Department of Social Policy and Social Work, University of York; Mr Philip Cutler, Forums Support Manager, Bradford Alliance on Community Care; Professor Brian Ferguson, Director of the Yorkshire and Humber Public Health Observatory; Professor Ruth Hall, Regional Director, Health Protection Agency, South West; Ms Amanda Hoey, Director, Consumer Health Consulting Limited; Mr Andrew Hopkin, Senior Assistant Director for Derby City Council; Dr Ann Hoskins, Deputy Regional Director of Public Health for NHS North West; Ms Muriel James, Secretary for the Northampton Healthy Communities Collaborative and the King Edward Road Surgery Patient Participation Group; Professor David R Jones, Professor of Medical Statistics in the Department of Health Sciences, University of Leicester; Dr Matt Kearney, General Practitioner, Castlefields, Runcorn and GP Public Health Practitioner, Knowsley; Ms Valerie King, Designated Nurse for Looked After Children for Northampton PCT, Daventry and South Northants PCT and Northampton General Hospital. Public Health Skills Development Nurse for Northampton PCT; Dr Catherine Law (Chair) Reader in Children's Health, Institute of Child Health, University College London; Ms Sharon McAteer, Health Promotion Manager, Halton PCT; Professor Klim McPherson, Visiting Professor of Public Health Epidemiology, Department of Obstetrics and Gynaecology, University of Oxford; Professor Susan Michie, Professor of Health Psychology, BPS Centre for Outcomes Research & Effectiveness, University College London; Dr Mike Owen, General Practitioner, William Budd Health Centre, Bristol; Ms Jane Putsey, Lay Representative. Chair of Trustees of the Breastfeeding Network; Dr Mike Rayner, Director of British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford; Mr Dale Robinson, Chief Environmental Health Officer, South Cambridgeshire District Council; Professor Mark Sculpher, Professor of Health Economics at the Centre for Economics (CHE), University of York; Dr David Sloan, Retired Director of Public Health; Dr Dagmar Zeuner, Consultant in Public Health, Islington PCT

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

All members of the Public Health Interventions Advisory Committee are required to make an oral declaration all potential conflicts of interest at the start of the consideration of each public health intervention appraisal. These declarations will be minuted and published on the National Institute for Health and Clinical Excellence (NICE) website.

Members are required to provide in writing an annual statement of current conflicts of interests, in accordance with the Institute's policy and procedures.

Potential members of the Public Health Programme Development Groups (PDG), and any individuals having direct input into the guidance (including expert peer reviewers), are required to provide a formal written declaration of personal interests. A standard form has been developed for this purpose which also includes the Institute's standard policy for declaring interests. This declaration of interest form should be completed before any decision about the involvement of an individual is taken.

Any changes to a Group member's declared conflicts of interests should also be recorded at the start of each PDG meeting. The PDG Chair should determine whether these interests are significant.  If a member of the PDG has a possible conflict of interest with only a limited part of the guidance development or recommendations, that member may continue to be involved in the overall process but should withdraw from involvement in the area of possible conflict. This action should be documented and be open to external review. If it is considered that an interest is significant in that it could impair the individual's objectivity throughout the development of public health guidance, he or she should not be invited to join the group.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

  • Workplace interventions to promote smoking cessation. Quick reference guide. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 6 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the National Institute for Health and Clinical Excellence (NICE) Web site.
  • Costing template: workplace health promotion: how to help employees to stop smoking. Full business case. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. Various p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Costing template: workplace health promotion: how to help employees to stop smoking. Simplified business case. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. Various p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Costing template: workplace health promotion: how to help employees to stop smoking. Summary business case. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 6 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Costing template: stop smoking legislation. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. Various p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Information for employers – what you can do to encourage your employees to stop smoking. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 1 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Slide set: workplace interventions to promote smoking cessation. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 18 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Implementation advice: workplace interventions to promote smoking cessation. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 19 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Audit criteria: workplace health promotion: how to help employees to stop smoking. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Apr. 10 p. (Public Health Intervention Guidance 5). Available in Portable Document Format (PDF) from the NICE Web site.
  • Methods for development of NICE public health guidance. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Oct. 131 p. Available in Portable Document Format (PDF) from the NICE Web site.

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455. ref: N1188. 11 Strand, London, WC2N 5HR.

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on June 20, 2007. The information was verified by the guideline developer on July 16, 2007. This summary was updated by ECRI Institute on October 31, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This summary was updated by ECRI Institute on July 20, 2009 following the U.S. Food and Drug Administration advisory on Varenicline and Bupropion.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo